ClinicalTrialsFinder

Triple-Negative Breast Cancer Clinical Trials in Capital Federal, Buenos Aires

1 recruitingCapital Federal, Buenos Aires, Argentina

Showing 1–1 of 1 trials

Recruiting
Phase 3

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Triple-Negative Breast Cancer
Merck Sharp & Dohme LLC1,530 enrolled281 locationsNCT06393374